Adaptive Biotechnologies Analyst Price Targets

Wall Street analyst price targets and consensus rating for Adaptive Biotechnologies (ADPT).

Price Target Range — 13 Quarters

Analyst Consensus — 7 Analysts

7Buy

Consensus RatingBuy# Analysts7Avg. Consensus PT$23Upside to Avg. PT-22.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$25→$32
Sep 29, 2026	Goldman Sachs	Evie Koslosky	Initiate	Buy	$35
Sep 22, 2026	BTIG	Mark Massaro	PT Raise	Buy	$25→$34
Aug 4, 2026	Piper Sandler	David Westenberg	PT Raise	Overweight	$20→$28
Jul 30, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$20→$22
Jul 30, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$25→$28
Jul 30, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$22→$25
Jul 30, 2026	BTIG	Mark Massaro	PT Raise	Buy	$24→$25
Jul 9, 2026	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$18→$20
Jun 29, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$21→$22
Jun 17, 2026	BTIG	Mark Massaro	Maintained	Buy	$22
May 12, 2026	Morgan Stanley	Tejas Savant	PT Cut	Equal-Weight	$21→$18
May 6, 2026	JP Morgan	Sebastian Sandler	PT Cut	Overweight	$21→$19
May 6, 2026	TD Cowen	Dan Brennan	PT Raise	Buy	$19→$21
May 6, 2026	Guggenheim	Subbu Nambi	Maintained	Buy	$21
May 6, 2026	BTIG	Mark Massaro	Maintained	Buy	$22
Feb 6, 2026	JP Morgan	Sebastian Sandler	PT Raise	Overweight	$20→$21
Feb 6, 2026	BTIG	Mark Massaro	PT Raise	Buy	$21→$22
Jan 26, 2026	Guggenheim	Subbu Nambi	PT Raise	Buy	$20→$21
Nov 11, 2025	Morgan Stanley	Tejas Savant	PT Raise	Equal-Weight	$11→$16

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $32.

Benzinga Newsdesk

PRO
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

Goldman Sachs analyst Evie Koslosky initiates coverage on Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy rating and announces Price Target of $35.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $34.

Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overweight and raises the price target from $20 to $27.5.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $25 to $28.

Benzinga Newsdesk

Adaptive Biotechnologies Corp

Adaptive Biotechnologies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PRO
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

People Also Watch

People Also Watch

Adaptive Biotechnologies Corp

Adaptive Biotechnologies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROGuggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PROGoldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

PROBTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

PROPiper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

PROMorgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

PROTD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

People Also Watch

People Also Watch

PRO
Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32

PRO
Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35

PRO
BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $34

PRO
Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

PRO
Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

PRO
TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28